Clinical Report: Impact of Anti-TNF α Treatment on Pediatric Uveitis
Overview
This study evaluates the effectiveness of anti-TNF-α therapy in children with refractory non-infectious uveitis in Saudi Arabia. The findings suggest significant improvements in visual acuity and reduced corticosteroid dependency following treatment.
Background
Pediatric uveitis is a rare but serious condition that can lead to vision loss and has a significant impact on affected children and their families. Traditional treatments often involve corticosteroids, which carry risks of adverse effects, particularly with long-term use. The advent of biologic therapies, such as anti-TNF-α agents, offers a promising alternative for managing severe cases that are unresponsive to conventional treatments.
Data Highlights
Parameter
Baseline
12 Months
Best Corrected Visual Acuity (BCVA)
LogMAR X
LogMAR Y
Corticosteroid Dosage
Z mg/day
A mg/day
Uveitis Relapse Rate
B relapses/year
C relapses/year
Key Findings
Anti-TNF-α therapy led to significant improvements in BCVA after 12 months.
Reduction in corticosteroid dosage was observed in most patients following anti-TNF-α treatment.
The frequency of uveitis relapses decreased significantly over the treatment period.
Both Infliximab and Adalimumab were effective in managing refractory cases.
Long-term follow-up indicated sustained benefits with minimal side effects.
Clinical Implications
The use of anti-TNF-α therapies in pediatric patients with refractory non-infectious uveitis can lead to improved visual outcomes and reduced reliance on corticosteroids. Clinicians should consider these biologic agents for managing severe cases, particularly when conventional treatments fail.
Conclusion
Anti-TNF-α therapy represents a valuable option for treating refractory non-infectious uveitis in children, with promising outcomes in visual acuity and steroid-sparing effects.
